JP2015516957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516957A5 JP2015516957A5 JP2015503681A JP2015503681A JP2015516957A5 JP 2015516957 A5 JP2015516957 A5 JP 2015516957A5 JP 2015503681 A JP2015503681 A JP 2015503681A JP 2015503681 A JP2015503681 A JP 2015503681A JP 2015516957 A5 JP2015516957 A5 JP 2015516957A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyrazin
- imidazo
- membered
- prop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 36
- -1 4-heptyl Chemical group 0.000 claims description 32
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 32
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 30
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 26
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 26
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 150000005829 chemical entities Chemical class 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 19
- 210000002027 skeletal muscle Anatomy 0.000 claims description 18
- RSQGZEAXODVTOL-UHFFFAOYSA-N 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RSQGZEAXODVTOL-UHFFFAOYSA-N 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229940125913 troponin activator Drugs 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- WYRAXYZTIXGPNA-QPJJXVBHSA-N 3-pentan-3-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C/C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-QPJJXVBHSA-N 0.000 claims description 6
- 206010003694 Atrophy Diseases 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 6
- 230000037444 atrophy Effects 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 5
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 4
- SSZGBXHOXMJQIV-NSCUHMNNSA-N 3-(oxan-4-yl)-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2N=C(O)N1C1CCOCC1 SSZGBXHOXMJQIV-NSCUHMNNSA-N 0.000 claims description 4
- SSZGBXHOXMJQIV-IHWYPQMZSA-N 3-(oxan-4-yl)-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCOCC1 SSZGBXHOXMJQIV-IHWYPQMZSA-N 0.000 claims description 4
- NSPIDWPREXAAAQ-QHHAFSJGSA-N 3-cyclohexyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-QHHAFSJGSA-N 0.000 claims description 4
- NSPIDWPREXAAAQ-KXFIGUGUSA-N 3-cyclohexyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-KXFIGUGUSA-N 0.000 claims description 4
- KUFBAWMESFZISC-NSCUHMNNSA-N 3-cyclopropyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-NSCUHMNNSA-N 0.000 claims description 4
- KUFBAWMESFZISC-IHWYPQMZSA-N 3-cyclopropyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-IHWYPQMZSA-N 0.000 claims description 4
- WYRAXYZTIXGPNA-DAXSKMNVSA-N 3-pentan-3-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-DAXSKMNVSA-N 0.000 claims description 4
- RKWUIYMGQOAXEZ-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-ynyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RKWUIYMGQOAXEZ-UHFFFAOYSA-N 0.000 claims description 4
- PFKZWBXZBQPWJI-SNAWJCMRSA-N 3-propan-2-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C\C1=CN=C2NC(=O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-SNAWJCMRSA-N 0.000 claims description 4
- PFKZWBXZBQPWJI-PLNGDYQASA-N 3-propan-2-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2N=C(O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-PLNGDYQASA-N 0.000 claims description 4
- SBJUQVUTJXSWQG-UHFFFAOYSA-N 5-ethenyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 SBJUQVUTJXSWQG-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 230000004220 muscle function Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- ZUKQRELSXSZGNR-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-en-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 ZUKQRELSXSZGNR-UHFFFAOYSA-N 0.000 claims description 3
- JMZLLOCPIPPQSP-UHFFFAOYSA-N 5-bromo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C1=C(Br)N=C2N(C(CC)CC)C(O)=NC2=N1 JMZLLOCPIPPQSP-UHFFFAOYSA-N 0.000 claims description 2
- GMOWAKFCILZILA-GFCCVEGCSA-N 5-ethynyl-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C([C@@H](CC)N1C2=NC(=CN=C2N=C1O)C#C)N1CCOCC1 GMOWAKFCILZILA-GFCCVEGCSA-N 0.000 claims description 2
- 208000003508 Botulism Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000007964 Organophosphate Poisoning Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000002151 Pleural effusion Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 238000005399 mechanical ventilation Methods 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 210000003105 phrenic nerve Anatomy 0.000 claims description 2
- 230000037081 physical activity Effects 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 claims 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619261P | 2012-04-02 | 2012-04-02 | |
| US61/619,261 | 2012-04-02 | ||
| PCT/US2013/034824 WO2013151938A1 (en) | 2012-04-02 | 2013-04-01 | Methods for improving diaphragm function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098858A Division JP2018131460A (ja) | 2012-04-02 | 2018-05-23 | 横隔膜機能を向上させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516957A JP2015516957A (ja) | 2015-06-18 |
| JP2015516957A5 true JP2015516957A5 (enExample) | 2016-06-02 |
| JP6345645B2 JP6345645B2 (ja) | 2018-06-20 |
Family
ID=49300969
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503681A Expired - Fee Related JP6345645B2 (ja) | 2012-04-02 | 2013-04-01 | 横隔膜機能を向上させるための方法 |
| JP2018098858A Ceased JP2018131460A (ja) | 2012-04-02 | 2018-05-23 | 横隔膜機能を向上させるための方法 |
| JP2020104620A Pending JP2020147607A (ja) | 2012-04-02 | 2020-06-17 | 横隔膜機能を向上させるための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098858A Ceased JP2018131460A (ja) | 2012-04-02 | 2018-05-23 | 横隔膜機能を向上させるための方法 |
| JP2020104620A Pending JP2020147607A (ja) | 2012-04-02 | 2020-06-17 | 横隔膜機能を向上させるための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150065525A1 (enExample) |
| EP (1) | EP2834269A4 (enExample) |
| JP (3) | JP6345645B2 (enExample) |
| KR (1) | KR20160046693A (enExample) |
| CN (2) | CN108553467A (enExample) |
| AU (2) | AU2013243671B2 (enExample) |
| BR (1) | BR112014024552A2 (enExample) |
| CA (1) | CA2868507A1 (enExample) |
| EA (1) | EA031183B1 (enExample) |
| HK (1) | HK1206364A1 (enExample) |
| IL (2) | IL234885A0 (enExample) |
| MX (1) | MX354965B (enExample) |
| PH (1) | PH12014502217A1 (enExample) |
| SG (2) | SG10201701101YA (enExample) |
| WO (1) | WO2013151938A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN109316480A (zh) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| BR112014025251B1 (pt) * | 2012-04-11 | 2021-03-02 | Fady Malik | uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| CA2903979A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| LT3137622T (lt) | 2014-04-29 | 2022-04-25 | Cytokinetics, Inc. | Gyvybinio pajėgumo nykimo mažinimo būdai |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| US9987279B2 (en) * | 2014-09-09 | 2018-06-05 | Astellas Pharma Inc. | Pharmaceutical composition for prevention and/or treatment of urinary incontinence |
| WO2016193844A1 (en) | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| SG11201806416XA (en) | 2016-02-12 | 2018-08-30 | Astellas Pharma Inc | Tetrahydroisoquinoline derivatives |
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| JP7687968B2 (ja) | 2019-06-19 | 2025-06-03 | エフ． ホフマン－ラ ロシュ アーゲー | デジタルバイオマーカー |
| CN114051390A (zh) * | 2019-06-19 | 2022-02-15 | 豪夫迈·罗氏有限公司 | 数字生物标志物 |
| JP7728184B2 (ja) | 2019-06-19 | 2025-08-22 | エフ． ホフマン－ラ ロシュ アーゲー | デジタルバイオマーカー |
| TW202116754A (zh) | 2019-07-11 | 2021-05-01 | 美商Ｅ 斯蓋普生物股份有限公司 | 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑 |
| JP7825618B2 (ja) | 2020-11-06 | 2026-03-06 | サイトキネティックス， インコーポレイテッド | 二環式１，４－ジアゼパノン及びその治療的使用 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| US20240382564A1 (en) * | 2023-04-17 | 2024-11-21 | Allysta Pharmaceuticals, Inc. | Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070173465A9 (en) * | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
| AU6814901A (en) * | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| CN1283793C (zh) * | 2002-06-03 | 2006-11-08 | 北京大学 | 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族 |
| JP2007501805A (ja) * | 2003-08-08 | 2007-02-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピリジルピペラジニルウレア |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| BRPI0714725B1 (pt) * | 2006-08-02 | 2021-05-25 | Cytokinetics, Inc | Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CN101821279A (zh) * | 2007-08-15 | 2010-09-01 | 赛特凯恩蒂克公司 | 某些化学个体、组合物和方法 |
| NL2001694C2 (en) * | 2008-06-18 | 2009-12-22 | Nasophlex B V | Ear stimulator for producing a stimulation signal to an ear. |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
-
2013
- 2013-04-01 WO PCT/US2013/034824 patent/WO2013151938A1/en not_active Ceased
- 2013-04-01 US US14/389,805 patent/US20150065525A1/en not_active Abandoned
- 2013-04-01 SG SG10201701101YA patent/SG10201701101YA/en unknown
- 2013-04-01 KR KR1020147027435A patent/KR20160046693A/ko not_active Abandoned
- 2013-04-01 CN CN201810509450.1A patent/CN108553467A/zh active Pending
- 2013-04-01 BR BR112014024552A patent/BR112014024552A2/pt not_active Application Discontinuation
- 2013-04-01 EA EA201491605A patent/EA031183B1/ru not_active IP Right Cessation
- 2013-04-01 SG SG11201406270YA patent/SG11201406270YA/en unknown
- 2013-04-01 CA CA2868507A patent/CA2868507A1/en not_active Abandoned
- 2013-04-01 JP JP2015503681A patent/JP6345645B2/ja not_active Expired - Fee Related
- 2013-04-01 CN CN201380018757.7A patent/CN104379597A/zh active Pending
- 2013-04-01 AU AU2013243671A patent/AU2013243671B2/en not_active Ceased
- 2013-04-01 MX MX2014011881A patent/MX354965B/es active IP Right Grant
- 2013-04-01 HK HK15106936.7A patent/HK1206364A1/xx unknown
- 2013-04-01 EP EP13773086.7A patent/EP2834269A4/en not_active Withdrawn
-
2014
- 2014-09-29 IL IL234885A patent/IL234885A0/en unknown
- 2014-10-01 PH PH12014502217A patent/PH12014502217A1/en unknown
-
2017
- 2017-02-27 US US15/444,063 patent/US20170266192A1/en not_active Abandoned
- 2017-12-07 AU AU2017272286A patent/AU2017272286B2/en not_active Ceased
-
2018
- 2018-05-23 JP JP2018098858A patent/JP2018131460A/ja not_active Ceased
-
2019
- 2019-07-05 IL IL267876A patent/IL267876B/en active IP Right Grant
-
2020
- 2020-06-17 JP JP2020104620A patent/JP2020147607A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540713A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| JP2011515482A5 (enExample) | ||
| JP2011529918A5 (enExample) | ||
| JP2016534134A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2020517707A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2015518903A5 (enExample) | ||
| JP2009532417A5 (enExample) | ||
| JP2017538678A5 (enExample) | ||
| JP2018529650A5 (enExample) | ||
| JP2016513663A5 (enExample) | ||
| JP2013505946A5 (enExample) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2016538720A5 (enExample) | ||
| JP2007535551A5 (enExample) | ||
| NO20063340L (no) | Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer | |
| JP2013508288A5 (enExample) | ||
| WO2010000372A3 (en) | New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | |
| JP2017501236A5 (enExample) |